arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Solid Biosciences Inc.

SLDB
$8.00 ▼ -0.90 (-10.11%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
39 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Solid Biosciences Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.1B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -12.1%
FCF / Share $-0.37
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-56.74M
↓ -44.4%
FCF / Share Free cash flow per share
$-0.37
↑ +8.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 39 quarters